Carcinoma, Ovarian Epithelial: all 1,619 studies
Page 15 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal CancerCompletedNCT00437502Phase 1
- Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer RelapseCompletedNCT00437307Phase 3
- Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedNCT00436254Phase 1
- Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00431054Phase 1
- Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian CarcinomaCompletedNCT00429559Phase 1/2
- Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian CancerCompletedNCT00428766Phase 1
- Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian CancerCompletedNCT00426257Phase 3
- Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by SurgeryCompletedNCT00410553Phase 1
- Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.WithdrawnNCT00408967Phase 2
- Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00408655Phase 1
- MITO-6: Capecitabine in Platinum Resistant Ovarian CancerCompletedNCT00403429Phase 2
- MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian CancerCompletedNCT00401674Phase 2
- Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerCompletedNCT00400348Phase 2
- Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian CancerCompletedNCT00383279Not applicable
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerCompletedNCT00382811Phase 3
- Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian CancerCompletedNCT00368420
- Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedNCT00357448Phase 1
- Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma CancerCompletedNCT00352300Phase 1
- Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian CarcinomaStatus unknownNCT00349505Phase 2
- AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00348699Phase 1
- Elizabeth Registry for Low Grade Ovarian CancerCompletedNCT00345709
- Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast CancerCompletedNCT00337233Not applicable
- Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic MalignanciesCompletedNCT00335998Phase 1
- Blood Test for Ovarian Cancer Associated Antibodies (CAAb)Status unknownNCT00327925
- MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian CancerStatus unknownNCT00326456Phase 3
- ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian CancerCompletedNCT00325351Phase 2
- Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian CancerTerminatedNCT00317434Phase 1
- Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer PatientsCompletedNCT00316407Phase 1/2
- Risk of Ovarian Cancer in Patients With a Pelvic MassCompletedNCT00315692
- Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal CancerCompletedNCT00314678Phase 2
- Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer TherapyCompletedNCT00312988Phase 3
- Doxil and Gemcitabine in Recurrent Ovarian CancerTerminatedNCT00312650Phase 2
- CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenStatus unknownNCT00305838Phase 2
- Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerTerminatedNCT00303888Phase 1
- Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic CancerCompletedNCT00295945
- CT-2106 for the Second Line Treatment of Ovarian CancerCompletedNCT00291837Phase 2
- Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00287859Phase 1
- Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.TerminatedNCT00287482Not applicable
- Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian CancerCompletedNCT00281515Phase 2
- Study of XL999 in Patients With Previously Treated Ovarian CancerTerminatedNCT00277290Phase 2
- Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00263822Phase 3
- Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian CancerCompletedNCT00261027Phase 2
- DOXIL for Consolidation Therapy in Ovarian Cancer.CompletedNCT00248248Phase 2
- Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)CompletedNCT00239980Phase 2
- Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic MassStatus unknownNCT00238342Not applicable
- Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT00230542Phase 2
- Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu VaccineCompletedNCT00228358Phase 1
- Treatment of Newly Diagnosed Ovarian Cancer With AntioxidantsCompletedNCT00228319Phase 1/2
- Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian CarcinomaCompletedNCT00226915Phase 3
- Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity CancerCompletedNCT00217568Phase 2
- Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00217529Phase 1/2
- Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based ChemotherapyCompletedNCT00216645Phase 2
- Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian CancerCompletedNCT00216112Phase 2
- Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal CancerCompletedNCT00214058Phase 2
- Weekly Topotecan Therapy in Patients With Ovarian CancerTerminatedNCT00194935Phase 2
- Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian CancerTerminatedNCT00189579Phase 2
- Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early RelapseCompletedNCT00189566Phase 2
- Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late RelapseCompletedNCT00189553Phase 3
- Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or PeritoneumTerminatedNCT00189371Phase 3
- A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based TherapyCompletedNCT00189358Phase 2
- Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer PatientsCompletedNCT00189345Phase 2
- Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian CancerCompletedNCT00181688Phase 2
- The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer PatientsStatus unknownNCT00173394
- Preference Study With Elderly Patients Recurrent Ovarian CancerCompletedNCT00170690Phase 3
- Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian CancerCompletedNCT00170677Phase 2
- Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian CancerCompletedNCT00170664Phase 2
- Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian CancerStatus unknownNCT00155896
- Mesothelin as a New Tumor Marker for Ovarian CancerStatus unknownNCT00155740
- IGFBP-3 in Ovarian Cancer InvasionStatus unknownNCT00154986Not applicable
- Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedNCT00138242Phase 2
- Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity CancerCompletedNCT00132067Phase 2
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
- Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian CancerCompletedNCT00113789Phase 2
- EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial CancerCompletedNCT00107445Phase 2
- Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune ResponseCompletedNCT00103545Phase 1/2
- Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian CancerTerminatedNCT00102622Phase 1
- Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian CancerCompletedNCT00102414Phase 3
- Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian CancerCompletedNCT00102375Phase 3
- Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00101257Phase 1
- Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the OvariesCompletedNCT00098800Not applicable
- Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian CancerCompletedNCT00097409Phase 2
- A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has FailedCompletedNCT00097019Phase 2
- Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian CancerCompletedNCT00096395Phase 2
- CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096239Phase 2
- Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00091377Phase 1/2
- Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity CancerTerminatedNCT00091195Phase 2
- Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
- Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00087087Phase 2
- Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentTerminatedNCT00086632Phase 2
- Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube CancersCompletedNCT00086567
- FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial CancerWithdrawnNCT00085527Phase 2
- Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
- Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic OophorectomyWithdrawnNCT00084370Not applicable
- Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 LevelsCompletedNCT00083928Phase 2
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00081276Phase 2
- CA-125 in Screening Patients at High Risk for Ovarian CancerWithdrawnNCT00080639
- Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00079430Phase 1
- Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial CancerStatus unknownNCT00075543Phase 1/2
- A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian CancerCompletedNCT00073541Phase 2